Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims

This article was originally published in The Tan Sheet

Executive Summary

A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus

You may also be interested in...



Fraudulent Zika Claims Are CDER's Latest Extermination Target

CDER is on the lookout for companies seeking to capitalize off the Zika health crisis with fraudulent claims about their products’ ability to treat or prevent the disease, says Brad Price, acting director of the Division of Nonprescription Drugs and Health Fraud, Office of Compliance.

Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements

FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola.

Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements

FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola.

Related Content

Topics

UsernamePublicRestriction

Register

PS103436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel